Antitumor activity of recombinant adenoviral vectors expressing murine IFN-α in mice injected with metastatic IFN-resistant tumor cells

Cancer Gene Therapy

Volumn 8, Issue 1, 2001, Pages 63-72

  Santodonato, Laura ^a   Ferrantini, Maria ^a   Palombo, Fabio ^b   Aurisicchio, Luigi ^b   Delmastro, Paola ^b   La Monica, Nicola ^b   Di Marco, Stefania ^b   Ciliberto, Gennaro ^b   Du, Mark X ^c   Taylor, Milton W ^c   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IRBM   (Italy)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Adenoviral vectors; Gene therapy; IFN ; Mice; Tumor

Indexed keywords

ALPHA1 INTERFERON; ALPHA2 INTERFERON; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FRIEND LEUKEMIA; GENE THERAPY; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS EXPRESSION;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0035125085     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700274     Document Type: Article

References (57)

1. Cytokine therapeutics: Lessons from interferon α
2. Role of interferons and other cytokines in the regulation of the immune response
3. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons
4. Safety profile of interferon-alpha therapy
5. The potential application of gene transfer in the treatment of patients with cancer: A concise review
6. Cytokines, tumor-cell death, and immunogenicity: A question of choice
7. Cancer vaccines
8. 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: Antitumor therapy by means of interferon-producing cells
9. + T-cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma producing TS/A cells
10. 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice
11. 1 transfected Friend leukemia cells
12. 1 gene transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to IFN-α/ β therapy
13. Interferon (IFN) -β gene transfer into TS/A adenocarcinoma cells and comparison with IFN-α. Differential effects on tumorigenicity and host response
14. 1 into syngeneic mice
15. Type I consensus Interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: Implications for new therapeutic strategies with IFN-α
16. Type I consensus IFN (IFN-con1) gene transfer into KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle activation via induction of apoptosis and abrogates tumorigenicity into SCID mice
17. Injection of irradiated melanoma genetically modified to secrete IFN-α causes regression of an established tumor
18. Interferon-α gene therapy for cancer: Retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models
19. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): Implications for live cancer vaccines
20. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models
21. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon α
22. In vivo tumor suppression by adenovirus-mediated interferon α2b gene delivery
23. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy
24. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells: II. Role of host mechanisms
25. Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of Friend erythroleukemia cells
26. Host humoral and cellular mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon α/β treatment in mice
27. Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression
28. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice
29. In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-α
30. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
31. T-cell- and NK-cell-independent inhibition of hepatic metastases by systemic administration of an II-12-expressing recombinant adenovirus
32. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: Efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models
33. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model
34. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
35. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM
36. Potent antitumor effects mediated by local expression of the mature form of the interferon-γ inducing factor, interleukin-18 (IL-18)
37. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models
38. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1
39. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model
40. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors
41. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model
42. Gene therapy for hepatic micrometastasis of murine colon carcinoma
43. Application of the cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer
44. The neglected role of type I interferon in the T-cell response: Implications for its clinical use
45. Isolation of interferon-resistant variants of Friend erythroleukemia cells: Effects of interferon and ouabain
46. Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells: I. Tumorigenicity and capacity to metastasize
47. Studies on the expression of spontaneous and induced interferons in mouse peritoneal macrophages by means of monoclonal antibodies to mouse interferons
48. Direct antiproliferative effects of recombinant human interferon-αB/D hybrids on human tumor cell lines
49. IFN-α hybrids
50. Heterologous gene expression in yeast
51. A deletion that includes the signal peptidase cleavage site impairs processing, glycosylation, and secretion of cell surface yeast acid phosphatase
52. Refolding, isolation and characterization of a crystallizable human interferon-α8 expressed in Saccharomyces cerevisiae
53. Liver specific alpha 2 interferon gene expression results in protection from induced hepatitis
54. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
55. Gene therapy of cancer with interferon: Lesson from tumor models and perspective for clinical application
56. Type I Interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-scid mice
57. Progressive glomerulonephritis in mice treated with interferon preparations at birth